HBM (HKG:2142) subsidiary Nona Biosciences and Candid Therapeutics signed a research collaboration and license agreement for next-generation T-cell engagers, according to a Monday filing with the Hong Kong Exchange.
As part of the deal, Nona will be able to receive $320 million in upfront and potential milestone payments, the report said.
Candid will take charge of the subsequent development of the T-cell engagers, which kill cancer cells, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.